Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine

BACKGROUND: Hydroxychloroquine (HCQ) is an antimalarial drug that is recommended as a safe, daily prophylactic intervention for individuals with systemic lupus erythematosus (SLE) based on previous studies that showed an association of HCQ use with reductions in flares compared with placebo. Our stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Aouhab, Z., Hong, H., Felicelli, C., Tarplin, S., Ostrowski, R. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857977/
https://www.ncbi.nlm.nih.gov/pubmed/31777844
http://dx.doi.org/10.1002/acr2.11084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857977/
https://www.ncbi.nlm.nih.gov/pubmed/31777844
http://dx.doi.org/10.1002/acr2.11084

Ejemplares similares